About us
Our comprehensive range includes the classic HD, classic 6.4, and pico (handheld) retinal imaging cameras, designed for adult patients. The 3nethra neo and neo HD FA stand out as the most advanced neonatal retinal imaging devices globally. Additionally, our 3nethra aberro and specto devices represent groundbreaking innovations in both objective and subjective refraction, ensuring that we meet diverse diagnostic needs with cutting-edge solutions.
Transforming Vision for Millions Globally
Forus Health is a medical device company transforming eye care through advanced technology and innovative solutions. By combining state-of-the-art devices, expert ophthalmologists and optometrists, and cutting-edge AI, we make advanced eye care accessible worldwide. Our 3nethra Series enhances the early detection, diagnosis, and management of ocular diseases, empowering healthcare professionals to improve patient outcomes. With over 3,800 installations across 73 countries, we’ve impacted 16 million lives by delivering high-quality eye care globally.
73+
Countries
16+
Million People
3800+
Installations
In addition to our comprehensive eye care solutions, we are advancing AI applications in healthcare. Our Diabetic Retinopathy AI, tested on a vast patient base, reflects our commitment to precision and quality. Beyond diabetic retinopathy, our AI tools support the early detection of glaucoma, macular degeneration, hypertensive retinopathy, and dry eye. We are also developing AI solutions that use retinal biomarkers to identify cardiovascular and autoimmune conditions, strengthening early detection and disease management. By integrating technology with healthcare, we continue to set new standards in medical excellence and expand access to advanced eye care.
History and Milestones
Forus Health was established in 2010 by with a vision to connect innovation and technology to empower healthcare providers and ensure quality eye care is accessible, affordable, and inclusive for all.
2010
- Forus Health was founded in Bangalore, India, with a mission to make eye care accessible and affordable.
- The name Forus signified the commitment to "FOR the USers” or “The Community"
- 3nethra classic was launched, enabling comprehensive eye screening.
- The first device was delivered to Aravind Eye Hospital.
2012 – 2013
- Forus Health introduced 3nethra royal, an advanced eye care solution.
- Secured $13.1 million in funding from Accel Partners, IDG Ventures, and Asian Health Fund.
- Launched cloud-based telemedicine features for remote diagnosis.
- Forus Health was recognized for affordability, portability, and suitability for rural areas.
2014 – 2015
- Introduced Clinical Decision Support System (CDSS) for diabetic retinopathy, glaucoma, and corneal opacity.
- Launched 3nethra flora, a digital mydriatic fundus camera for high-contrast retinal imaging.
- Expanded global presence and enhanced telemedicine capabilities.
2016 – 2017
- Partnered with Apollo Telehealth to establish one of the largest tele-ophthalmology programs.
- Introduced 3nethra neo, a portable device for early detection of Retinopathy of Prematurity (ROP).
- Opened a new office in the United States, marking a significant milestone in global expansion.
2018 – 2019
- Raised $3 million in Series C funding from AHF, Accel Partners, and Teamfund.
- Launched 3nethra aberro, a hand-held device for home-based refraction measurement.
- Introduced 3nethra classic HD, featuring lipid layer interferometry for tear film analysis and high-resolution imaging.
- Expanded focus to systemic diseases through ocular biomarkers.
- Launched FH TeleCare, a digital health platform for AI-driven remote diagnostics.
2020 – 2021
- Secured $2 million in Series D funding from Teamfund.
- Advanced diagnostic capabilities by integrating artificial intelligence (AI) and machine learning.
- Released 3nethra classic 6.4, a portable retinal screening device.
- Introduced 3nethra specto, enabling remote retinal screening without an optometrist.
- Launched the FH-TeleEye app for AI-powered remote eye screenings.
- Launched 3nethra neo HD, providing high-definition imaging for ROP detection.
2023 – 2024
- Unveiled FH-POISE (Platform for Ocular Intelligence for Systemic and Eye Diseases), an AI-driven platform for predictive healthcare.
- Launched 3nethra specto in the US, pioneering Digital Optometry as a Service (DoaaS).
- Introduced 3nethra pico, enabling retinal imaging in home settings.
2025
- Forus Health celebrates its 15th anniversary, reflecting years of innovation in eye care and healthcare technology.
Investors
The Forus Health Advantage: Technology for Accessible Eye Care
Trusted by Visionaries: Our Esteemed Investors
Our journey to transform eye care is supported by visionary investors who believe in our mission to make advanced eye care accessible worldwide. Their trust and backing drive our innovation and growth.
The Forus Health Advantage: Technology for Accessible Eye Care
Market Opportunity
The growing prevalence of vision impairment, which affects an estimated 10 million people worldwide, is driving the rapid global demand for affordable and accessible eye care solutions. Forus Health addresses this critical healthcare challenge with innovative, cost-effective technologies that make quality eye care accessible to all, regardless of geographic or economic barriers.
Our solutions empower healthcare providers with advanced tools for early detection, diagnosis, and management of eye conditions, bridging the gap between need and access. By combining cutting-edge technology with affordability, Forus Health transforms the delivery of eye care globally, ensuring everyone benefits in the pursuit of better vision and healthier lives.
Proven Track Record
Successfully deployed devices across 73+ countries.
Over 10 million eyes have been screened globally.
Strategic partnerships with governments, healthcare organizations, and NGOs.
Innovation at the Core
Forus Health leads in AI integration, telemedicine, and portable diagnostic devices, making eye care more efficient and inclusive. Our research and development team focuses on continuous innovation, addressing retinal diseases, systemic health conditions, and enhancing early diagnostics.
Sustainable Impact
Our solutions are designed to bridge the gap in healthcare access, contributing to Sustainable Development Goals (SDGs) such as
good health, well-being, and reduced inequalities.
Technology Leadership
Proprietary AI-driven technologies like FH-POISE and a robust product portfolio focused on innovation, precision and accessibility.
Scalable Business Model
A combination of device sales, AI-powered SaaS solutions, and long-term service agreements ensures recurring revenue streams.
Global Presence
Operations spanning US, Asia, Europe, and Africa with a strong growth trajectory in emerging markets.
Experienced Leadership
A dedicated team with deep expertise in healthcare, technology, and business strategy.
Growth Strategy
We aim to penetrate new markets in Europe and Latin America while strengthening our presence in US, India and Africa.
Expanding our portfolio to include advanced diagnostic and therapeutic solutions, leveraging AI to address systemic and eye health.
Collaborating with governments, hospitals, and non-profit organizations to scale the impact of our solutions.
Continuously investing in R&D to stay ahead of technological advancements and meet evolving healthcare needs.
